Wuxi Biologics Cayman Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wuxi Biologics Cayman Inc with three other
pharmaceutical manufacturers in Asia:
Tianjin Ringpu Bio-Technology Co Ltd
sales of 969.68 million Chinese Renmimbi [US$153.38 million]
of which 63%
was Veterinary Biological Products),
Beijing SL Pharmaceutical Co Ltd
(1.01 billion Chinese Renmimbi [US$159.74 million]
of which 98%
was Pharmaceuticals Industry), and
Boya Bio-pharmaceutical Group Co Ltd
based in China
(946.57 million Chinese Renmimbi [US$149.73 million]
of which 56%
was Blood Plasma).